Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial

被引：0
|
作者：
Martin, M. [1 ]
Holmes, F. A. [2 ]
Moy, B. [3 ]
Mansi, J. [4 ,5 ]
Gnant, M. [6 ]
Buyse, M. [7 ]
Barrios, C. [8 ]
Bryce, R. [9 ]
Wong, A. [9 ]
Chan, A. [10 ,11 ]
机构：
[1] Univ Complutense Madrid, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[2] Texas Oncol, US Oncol, Houston, TX USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] Kings Coll London, Biomed Res Ctr, London, England
[6] Med Univ Vienna, Vienna, Austria
[7] Int Inst Drug Dev, San Francisco, CA USA
[8] Pontificia Univ Catolica Rio Grande do Sul, Ctr Pesquisa Oncol HSL, Porto Alegre, RS, Brazil
[9] Puma Biotechnol Inc, Los Angeles, CA USA
[10] Breast Canc Res Ctr WA, Perth, WA, Australia
[11] Curtin Univ, Nedlands, WA, Australia
来源：
BREAST | 2021年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P005
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [1] Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial
    Holmes, Frankie Ann
    Moy, Beverly
    Delaloge, Suzette
    Chia, Stephen
    Ejlertsen, Bent
    Mansi, Janine
    Iwata, Hiroji
    Gnant, Michael
    Buyse, Mark
    Barrios, Carlos
    Silovski, Tajana
    Separovic, Robert
    Bashford, Anna
    Guerrero-Zotano, Angel
    Denduluri, Neelima
    Patt, Debra
    Gokmen, Erhan
    Gore, Ira
    Smith, John
    Bryce, Richard
    Xu, Feng
    Wong, Alvin
    Martin, Miguel
    Chan, Arlene
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [2] Continued Efficacy of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer: Final Overall Survival Analysis From the Randomized Phase 3 ExteNET Trial
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 17 - 17
  • [3] Continued Efficacy of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer: Final Overall Survival Analysis From the Randomized Phase 3 ExteNET Trial
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 5 - 6
  • [4] Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
    Chan, Arlene
    Moy, Beverly
    Mansi, Janine
    Ejlertsen, Bent
    Holmes, Frankie Ann
    Chia, Stephen
    Iwata, Hiroji
    Gnant, Michael
    Loibl, Sibylle
    Barrios, Carlos H.
    Somali, Isil
    Smichkoska, Snezhana
    Martinez, Noelia
    Alonso, Mirta Garcia
    Link, John S.
    Mayer, Ingrid A.
    Cold, Soren
    Murillo, Serafin Morales
    Senecal, Francis
    Inoue, Kenichi
    Ruiz-Borrego, Manuel
    Hui, Rina
    Denduluri, Neelima
    Patt, Debra
    Rugo, Hope S.
    Johnston, Stephen R. D.
    Bryce, Richard
    Zhang, Bo
    Xu, Feng
    Wong, Alvin
    Martin, Miguel
    [J]. CLINICAL BREAST CANCER, 2021, 21 (01) : 80 - +
  • [5] Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial
    Chan, A.
    Moy, B.
    Mansi, J. L.
    Gnant, M. I.
    Barrios, C. H.
    Separovic, R.
    Guerrero-Zotano, A.
    Gore, I.
    Smith, J.
    Bryce, R. P.
    Xu, F.
    Wong, A.
    Martin, M.
    Holmes, F. A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S40 - S40
  • [6] Neratinib in Early-Stage HER2-Positive Breast Cancer
    Cherian, Mathew A.
    Ma, Cynthia X.
    [J]. BREAST DISEASES, 2015, 26 (04): : 285 - 287
  • [7] Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Earlystage Breast Cancer From the Phase III ExteNET Trial
    Lichert, Frank
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (05)
  • [8] Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
    Barcenas, C. H.
    Hurvitz, S. A.
    Di Palma, J. A.
    Bose, R.
    Chien, A. J.
    Iannotti, N.
    Marx, G.
    Brufsky, A.
    Litvak, A.
    Ibrahim, E.
    Alvarez, R. H.
    Ruiz-Borrego, M.
    Chan, N.
    Manalo, Y.
    Kellum, A.
    Trudeau, M.
    Thirlwell, M.
    Saenz, J. Garcia
    Hunt, D.
    Bryce, R.
    McCulloch, L.
    Rugo, H. S.
    Tripathy, D.
    Chan, A.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (09) : 1223 - 1230
  • [9] Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial
    Delaloge, S.
    Cella, D.
    Ye, Y.
    Buyse, M.
    Chan, A.
    Barrios, C. H.
    Holmes, F. A.
    Mansi, J.
    Iwata, H.
    Ejlertsen, B.
    Moy, B.
    Chia, S. K. L.
    Gnant, M.
    Smichkoska, S.
    Ciceniene, A.
    Martinez, N.
    Filipovic, S.
    Ben-Baruch, N. E.
    Joy, A. A.
    Langkjer, S. T.
    Senecal, F.
    de Boer, R. H.
    Moran, S.
    Yao, B.
    Bryce, R.
    Auerbach, A.
    Fallowfield, L.
    Martin, M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (04) : 567 - 574
  • [10] The impact of neoadjuvant chemotherapy on overall survival in patients with early-stage HER2-positive breast cancer
    Champion, Nicholas
    Azab, Basem
    Abeysekera, Aravinda
    Kim, Sara
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 1) : 201 - 201
12345